About us

ABOUT US

CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system.

CAP-Go enables the production of proteins “beyond antibodies”. Complex, glycosylated proteins represent a significant portion of the human proteome and are notoriously difficult to express in conventional cell lines such as CHO. The CAP-Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor-made glycosylation patterns.

CAP-GT is a fully scalable manufacturing platform for viral vector production. CEVEC has successfully developed CAP-GT suspension cell-derived viral packaging cell lines, including a stable, helper virus-free AAV production platform, which enable better scale-up and competitive production costs when compared to adherent cell culture systems. CAP-GT suspension cell lines grow to high cell densities and show excellent productivity for a broad range of viruses. Gene therapy vectors such as lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV) can be produced at industrial scale.

Follow CEVEC on LinkedIn.

Management

Dr. Nicole Faust has extensive management experience in the biotechnology sector. Over the last 18 years she has held scientific management positions with Artemis/Taconic Biosciences, amaxa, Lonza, and CEVEC, engaging in the fields of pharmaceutical models, gene transfer, protein production, and gene therapy. She received her Ph.D. from University of Freiburg and an MBA degree from Educatis University, Switzerland.

DR. NICOLE FAUST

Chief Executive Officer

Dr. Silke Wissing has wide-ranging experience in the fields of virology, cell biology and cell line development, as well as molecular biology. Before joining CEVEC in 2011, she held a position as a group leader in the Gladstone Institute for Virology and Immunology, San Francisco, where she performed research in the field of HIV-1 biology, stem cell research and cell line development. Dr. Silke Wissing holds a PhD in Biochemistry from the University of Tübingen.

DR. Silke Wissing

Chief Scientific Officer

Dr. Ulrich Kettling is CBO at CEVEC Pharmaceuticals. Before joining CEVEC in 2018 as VP Business Development, Dr. Kettling served in various commercial and technical roles, including Head of Market Segment Enzymes and Head of R&D, Group Biotechnology at Clariant; Global Director Biotechnology at Süd-Chemie; CSO at Direvo Biotech. He graduated in Biotechnology and obtained a Ph.D. in Biophysical Chemistry at the Max Planck Institute in Göttingen.

DR. Ulrich Kettling

Chief Business Officer

Dr. Nadine Sandhöfer joined CEVEC in 2015. She holds a PhD in human biology with a strong scientific background in tumor biology and in the field of targeted therapies. As a scientist and research manager, Nadine held positions with the Helmholtz Center Munich and the DKFZ Heidelberg. During her position in an ISO certified medical laboratory at the University Hospital Munich, she was trained and certified as quality management representative and internal auditor.

DR. NADINE SANDHÖFER

Director QA and Regulatory Affairs

Board

BART BERGSTEIN

Cofounder of Forbion Capital Partners
Former Life Science Venture Capitalist

KARLHEINZ SCHMELIG

Managing Partner
at Creathor Venture

DR. ARISTOTELIS NASTOS

Head of Life Sciences
at NRW Bank Venture Fund

DR. JOACHIM RAUTTER

Partner at PEPPERMINTVENTURE PARTNERS
Chairman of the Board

DR. KLAUS ZIMMERMANN

Barrister-at-law

DR. MED MARTIN WIRTZ

VP Business Development & Strategy Pall

Scientific Advisory Board CAP®Go

PROF. DR. JÜRGEN HUBBUCH

Professor at Karlsruhe Institute of Technology
Head of the Institute of Engineering in Life
Section IV: Biomolecular Separation Engineering

PROF. DR. THOMAS NOLL

Professor and Chair for Cell Culture Technology
University of Bielefeld

Franz Nothelfer

Former Associate Director Protein Science
Boehringer Ingelheim Pharma GmbH & Co.KG

Scientific Advisory Board CAP®GT

PROF. DR. STEFAN KOCHANEK

Professor at the University of Ulm
and Director of the Department of Gene Therapy

DR. OTTO MERTEN

Specialist in gene therapy/vector manufacturing
Miltenyi Biotec

Dr. J. Fraser Wright

Professor of Pediatrics
Center for Definitive and Curative Medicine
Stanford University School of Medicine

Investors

GAT Holding (Switzerland), CEVEC’s Chief Executive Officer and Chief Business Officer as well as other private investors are complementing the investor base of CEVEC Pharmaceuticals GmbH